ArticleTechnical innovations & patient support in radiation oncology2025
Exploratory health economic analyses to support decisions within the innovation process in radiotherapy: Magnetic Resonance Linear Accelerator as a case study.
Article in Technical innovations & patient support in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Human papillomavirus (HPV) infection and prevalence of colorectal cancer: an updated systematic review and meta-analysis of global data.International journal of surgery (London, England) · 2026Pooled it
- Integrative Multiomics and Single-Cell Analyses Identify FKBP10 as a Predictor of Radiotherapy Outcome in Colorectal Cancer.Human mutation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: There is an increasing need for understanding the added value of radiotherapeutic innovations before their widespread adoption. For multi-purpose innovations such as the Magnetic Resonance Linear Accelerator (MR-Linac), determining their value within a specific clinical context does not conclusively answer the broader question whether the innovation justifies the required investment. Exploratory analyses can be informative during early development and use of the innovation. We aim to develop and demonstrate an online, flexible tool to facilitate early economic evaluation of the MR-Linac. Materials and methods: We developed a tool that enables users to compare the total costs and incremental effects needed of MRI-guided radiotherapy (MRIgRT) with conventional treatment by inputting data specific to their context. Costs included in the tool are both medical technology and personnel-related expenses. The effects, required to justify potential additional costs, are expressed in Quality Adjusted Life Years (QALYs). By default, input values are used tailored to the Dutch clinical context. Results: When users input data specific to their context or situation, the tool generates figures that display the (additional) costs and effects of MRIgRT compared to conventional treatment. These figures enable users to explore the impact of key variables on the (additional) costs and QALYs required to justify any potential extra costs associated with MRIgRT. Conclusion: The tool and accompanying example allow for exploratory early HTA analyses, which can offer insights into the cost-effectiveness of MRIgRT. These insights can be valuable for guiding decisions regarding the purchase and utilization of innovative radiotherapeutic technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.